Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment
Journal of Controlled Release · 2025-03 · 379 · 621-635
DOI: 10.1016/j.jconrel.2025.01.042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Flávia Castro und 14 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade d…. Hauptthemen laut MEDLINE: Chitosan, Interferon-gamma, Polyglutamic Acid, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universiteit Gent, Carlos III Health Institute, Foundation for Science and Technology.
Abstract (Originalsprache)
Interferon-γ (IFN-γ) is a key mediator in antitumor immunity and immunotherapy responses, yet its clinical applications remain restricted to chronic granulomatous disease and malignant osteopetrosis. IFN-γ effectiveness as a standalone treatment has shown limited success in clinical trials and its potential for synergistic effects when combined with immunotherapies is under clinical exploration. A particularly compelling combination is that of IFN-γ with Toll-like receptor (TLR) agonists that holds significant promise for cancer treatment. Previously, we demonstrated chitosan (Ch)/poly(γ-glutamic acid) (γ-PGA) nanoparticles (NPs), known to activate TLRs, as adjuvants to radiotherapy by remodeling breast tumor microenvironment and systemic immunosuppression. These immunomodulatory abilities make Ch/γ-PGA NPs promising adjuvants to IFN-γ-based therapies. Here, we addressed the synergistic therapeutic potential of combining Ch/γ-PGA NPs with IFN-γ therapy in the 4T1 orthotopic breast tumor mouse model. While control animals (placebo-treated) had progressive tumor growth and lung metastases, those treated with either NPs or IFN-γ alone had a significant slower tumor growth. Remarkably, primary tumor growth was halted throughout the duration of the treatment when both treatments were combined. Although the animals did not achieve durable complete responses upon treatment withdrawal, it was notable that the NPs plus IFN-γ group presented a lower lung metastatic burden compared to other groups. Systemically, the combination therapy slightly attenuated immunosuppression and the percentage of splenic myeloid cells, while increased the percentage of T helper 1 cells and of cytotoxic T cells. Overall, this proof-of-concept study suggests that Ch/γ-PGA NPs potentiate IFN-γ effects to reduce tumor progression, presenting a novel approach for anticancer strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal. Electronic address: flaviateixeiracastro@ine…
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal.
- GIMM - Gulbenkian Institute for Molecular Medicine, Avenida Prof. Egas Moniz, Lisboa, Portugal.
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal; ICBAS - Instituto de Ciências Biomédicas Abe…
- Tumor Immunology Laboratory, Department of Pulmonary Medicine and Immuno-Oncology Network Ghent, Ghent University Hospital, Ghent, Belgium; CRIG - Cancer Research Institute Ghent, Ghent University, Belgium.
Förderung
- Universiteit Gent
- Carlos III Health Institute
- Foundation for Science and Technology
- European Regional Development Fund
- Ministerio de Ciencia, Innovación y Universidades
- Chartered Institute of Management Accountants
- Universidad de Navarra
- European Commission
Zitieren
APA
Castro, F., Pinto, M. L., Leite Pereira, C., Serre, K., Costa, Â. M., Cavadas, B., Barbosa, M. A., Vermaelen, K., León, S., Serrano, D., Gärtner, F., Calvo, A., Gonçalves, R. M., De Wever, O., & Oliveira, M. J. (2025). Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment. Journal of Controlled Release, 379, 621-635. https://doi.org/10.1016/j.jconrel.2025.01.042
Vancouver
Castro F, Pinto ML, Leite Pereira C, Serre K, Costa ÂM, Cavadas B, et al. Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment. Journal of Controlled Release. 2025;379:621-635. doi:10.1016/j.jconrel.2025.01.042
BibTeX
@article{Castro2025,
author = {Castro, Flávia and Pinto, Marta Laranjeiro and Leite Pereira, Catarina and Serre, Karine and Costa, Ângela Margarida and Cavadas, Bruno and Barbosa, Mário Adolfo and Vermaelen, Karim and León, Sergio and Serrano, Diego and Gärtner, Fátima and Calvo, Alfonso and Gonçalves, Raquel Madeira and De Wever, Olivier and Oliveira, Maria José},
title = {Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment},
journal = {Journal of Controlled Release},
year = {2025},
volume = {379},
pages = {621--635},
doi = {10.1016/j.jconrel.2025.01.042}
}
EUVIMED